CONCLUSION: The results of this study corroborate earlier findings that human papillomavirus (HPV)16 is the most prevalent type of HPV in squamous cell carcinomas of the head and neck (SCCHNs) and reinforce a possible influence of HPV on SCCHN progression by showing that the majority of HPV-positive patients harbor HPV16 (or HPV33) both in their primary tumors and in lymph node neck metastases (LNNMs). OBJECTIVE: HPVs are causally associated with carcinomas of the uterine cervix and have also been linked to a subset of SCCHNs. In order to further investigate the predicted causative role of HPV in SCCHNs, we analyzed pairs of primary tumors and LNNMs or LNNMs alone for the presence of HPV DNA using polymerase chain reaction (PCR). MATERIAL AND METHODS: DNA was extracted from fresh frozen tissue samples of primary tumors and the corresponding LNNMs of 18 patients and from LNNMs alone in 17 patients. For the detection and typing of HPV, PCR was performed using both type-specific and consensus primer pairs, followed by Southern hybridization and, in selected cases, sequencing of the PCR products. RESULTS: Of the 35 patients investigated, 22 (63%) were found to have HPV DNA in their tumors: HPV16 DNA in 21 cases and HPV33 in 1. The highest HPV prevalence was detected in tumors of Waldeyer's tonsillar ring (8/9 patients; 89%). Of the 18 patients in whom primary tumors and LNNMs were analyzed, 7 (39%) were HPV-positive in both samples (HPV16, n = 6; HPV33, n = 1), in 3 (17%) the primary tumors were HPV-negative and the LNNMs HPV16-positive and in 1 (5.5%) the primary tumor contained HPV16 and the LNNM was negative. Interestingly, of the 7 patients in whom LNNMs had been detected only several months after diagnosis and treatment of the primary tumors, only 1 showed infection with HPV (HPV33).
CONCLUSION: The results of this study corroborate earlier findings that human papillomavirus (HPV)16 is the most prevalent type of HPV in squamous cell carcinomas of the head and neck (SCCHNs) and reinforce a possible influence of HPV on SCCHN progression by showing that the majority of HPV-positive patients harbor HPV16 (or HPV33) both in their primary tumors and in lymph node neck metastases (LNNMs). OBJECTIVE: HPVs are causally associated with carcinomas of the uterine cervix and have also been linked to a subset of SCCHNs. In order to further investigate the predicted causative role of HPV in SCCHNs, we analyzed pairs of primary tumors and LNNMs or LNNMs alone for the presence of HPV DNA using polymerase chain reaction (PCR). MATERIAL AND METHODS: DNA was extracted from fresh frozen tissue samples of primary tumors and the corresponding LNNMs of 18 patients and from LNNMs alone in 17 patients. For the detection and typing of HPV, PCR was performed using both type-specific and consensus primer pairs, followed by Southern hybridization and, in selected cases, sequencing of the PCR products. RESULTS: Of the 35 patients investigated, 22 (63%) were found to have HPV DNA in their tumors: HPV16 DNA in 21 cases and HPV33 in 1. The highest HPV prevalence was detected in tumors of Waldeyer's tonsillar ring (8/9 patients; 89%). Of the 18 patients in whom primary tumors and LNNMs were analyzed, 7 (39%) were HPV-positive in both samples (HPV16, n = 6; HPV33, n = 1), in 3 (17%) the primary tumors were HPV-negative and the LNNMs HPV16-positive and in 1 (5.5%) the primary tumor contained HPV16 and the LNNM was negative. Interestingly, of the 7 patients in whom LNNMs had been detected only several months after diagnosis and treatment of the primary tumors, only 1 showed infection with HPV (HPV33).
Authors: Ioannis N Mammas; George Sourvinos; Apostolos Zaravinos; Demetrios A Spandidos Journal: Pathol Oncol Res Date: 2010-07-18 Impact factor: 3.201
Authors: Jos Straetmans; Julia Vent; Martin Lacko; Ernst-Jan Speel; Christian Huebbers; Robert Semrau; Frank Hoebers; Zlatan Mujagic; Jens-Peter Klussmann; Simon F Preuss; Bernd Kremer Journal: Eur Arch Otorhinolaryngol Date: 2014-03-11 Impact factor: 2.503
Authors: Julia E Heck; Julien Berthiller; Salvatore Vaccarella; Deborah M Winn; Elaine M Smith; Oxana Shan'gina; Stephen M Schwartz; Mark P Purdue; Agnieszka Pilarska; Jose Eluf-Neto; Ana Menezes; Michael D McClean; Elena Matos; Sergio Koifman; Karl T Kelsey; Rolando Herrero; Richard B Hayes; Silvia Franceschi; Victor Wünsch-Filho; Leticia Fernández; Alexander W Daudt; Maria Paula Curado; Chu Chen; Xavier Castellsagué; Gilles Ferro; Paul Brennan; Paolo Boffetta; Mia Hashibe Journal: Int J Epidemiol Date: 2009-12-18 Impact factor: 7.196
Authors: Alice Y Chuang; Tony C Chuang; Steven Chang; Shaoyu Zhou; Shahnaz Begum; William H Westra; Patrick K Ha; Wayne M Koch; Joseph A Califano Journal: Oral Oncol Date: 2008-03-07 Impact factor: 5.337
Authors: David Hebbelstrup Jensen; Nora Hedback; Lena Specht; Estrid Høgdall; Elo Andersen; Marianne Hamilton Therkildsen; Lennart Friis-Hansen; Bodil Norrild; Christian von Buchwald Journal: PLoS One Date: 2014-11-04 Impact factor: 3.240
Authors: Markus Hoffmann; Elgar S Quabius; Silke Tribius; Lena Hebebrand; Tibor Görögh; Gordana Halec; Tomas Kahn; Jürgen Hedderich; Christoph Röcken; Jochen Haag; Tim Waterboer; Markus Schmitt; Anna R Giuliano; W Martin Kast Journal: Oncol Rep Date: 2013-03-05 Impact factor: 3.906